

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

(Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/64090> since

Published version:

DOI:10.1021/jm900587h

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:

Questa è la versione dell'autore dell'opera:

[J. Med. Chem. 2009, 52, DOI: 10.1021/jm900587h]

ovvero [Loretta Lazzarato, Monica Donnola, Barbara Rolando, Konstantin Chegaev, Elisabetta Marini, Clara Cena, Antonella Di Stilo, Roberta Fruttero, Stefano Biondi, Ennio Ongini, and Alberto Gasco, J. Med. Chem. 2009, 52, 5058–5068]

The definitive version is available at:

La versione definitiva è disponibile alla URL:

[pubs.acs.org/jmc]

(Nitrooxyacyloxy)methyl Esters of Aspirin as Novel Nitric Oxide Releasing Aspirins

*Loretta Lazzarato,¹ Monica Donnola,¹ Barbara Rolando,¹ Konstantin Chegaev,¹ Elisabetta Marini,¹
Clara Cena,¹ Antonella Di Stilo,¹ Roberta Fruttero,¹ Stefano Biondi,² Ennio Ongini,² Alberto Gasco^{1,*}*

¹Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Via Pietro Giuria
9, 10125 Torino, Italy

²Nicox Research Institute, Via Ariosto 21, 20091, Bresso (Milano), Italy

E-mail address: alberto.gasco@unito.it

- To whom correspondence should be addressed. Tel: +39-011-670-7670. Fax: +39-011-670-7286. E-mail: alberto.gasco@unito.it.

^a Abbreviations: NSAIDs, non-steroidal anti-inflammatory drugs; PRP, platelet rich plasma; NO, nitric oxide; sGC, soluble guanylate cyclase; ODQ, 1*H*-[1,2,4]oxadiazolo[4,3-*a*]quinoxalin-1-one.

Abstract. A series of (nitrooxyacyloxy)methyl esters of aspirin were synthesised and evaluated as new NO-donor aspirins. Different amounts of aspirin were released in serum from these products according to the nature of nitrooxyacyloxy moiety present. In the aromatic series there is a rather good linear correlation between the amount of aspirin released and the potencies of the products in inhibiting platelet aggregation induced by collagen. Both the native compounds and the related nitrooxy-substituted acid metabolites were able to relax rat aorta strips precontracted with phenylephrine, in keeping with a NO-induced activation of the sGC as a mechanism which underlies the vasodilator

effect. The products here described are new improved examples of NO-donor aspirins containing nitrooxy groups. They could represent an alternative to the use of aspirin in a variety of clinical applications.

KEYWORDS: organic nitrates, NO-aspirins, NO-NSAIDs, multitarget drugs.

Introduction

Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used agents for the treatment of pain and inflammation. Over 30 million people are treated with these products every day.¹ The prototype of NSAIDs is aspirin which, in addition to anti-inflammatory and analgesic properties, displays antithrombotic effects, and consequently, protects against ischemic vascular disorders, including myocardial and cerebral infarction. It also exerts some beneficial effects against colorectal cancer.²⁻⁵ The activities of aspirin are largely due to its ability to inhibit irreversibly COX enzymes, preferentially the COX-1 isoform with respect to COX-2.^{6,7} The most important limit in using this drug is its strong gastrotoxicity due to systemic and local irritant effects.^{6,7} The former are thought to be dependent on the inhibition of COX-1 isoform, which is largely expressed in the gastric epithelial cells, the latter are closely associated with the presence in the molecule of a free carboxylic group. A strategy followed to reduce the local gastric drawback was the masking of this function through pro-drug formation. Indeed a number of these compounds display reduced gastrotoxicity.⁸ However, the problem with this approach is the high enzymatic liability of the *o*-acetyloxy group in these products. This is due to the loss of the negative charge which is present in aspirin at physiologic conditions following dissociation of its carboxylic function ($pK_a = 3.5$).⁹ Consequently a large part of these substances are not true pro-drugs since they are rapidly metabolised to salicylic acid in human serum without any formation of relevant amounts of aspirin. Another strategy to decrease the gastrotoxicity of aspirin is the combination of aspirin with nitric oxide (NO)-donor moieties. Indeed it is known that NO is able to display gastrosparring actions through a number of mechanisms.¹⁰ In addition, it is able to maintain

micro and macrovascular homeostasis¹¹⁻¹³ as well as to trigger anti-inflammatory and analgesic effects.¹⁴ Therefore, this “gaseous solution” to the old problem of aspirin gastrotoxicity received great attention. A number of NO-donor moieties have been joined through an ester linkage to the carboxylic group of the drug. They include substructures containing nitrooxy functions,^{15,16} furoxan¹⁷ and *N*-diazoniumdiolate moieties (Chart 1).¹⁸⁻²⁰ The former two classes of products are rapidly metabolised in serum, plasma and a number of cell fractions with little or no formation of aspirin,^{16,21-23} while for the latter no specific study of aspirin release has been reported thus far. In this paper we describe a new class of (nitrooxyacyloxy)methyl esters of this drug, showing that a number of them are stable in acid and in physiological pH solution but are able to release relevant amount of aspirin when incubated in human serum. This double ester moiety was chosen in view its rapid hydrolysis in serum.²⁴ Antiaggregatory and NO-dependent vasodilator properties of all these new products are discussed as well.

Results and Discussion

Chemistry. The development of this new class of NO-donor aspirins required the availability of a number of nitrooxy substituted carboxylic acids. Products **1-4**, **14**, **19**, **26** were obtained following procedures already described in literature, while acids **11-13**, **18**, **21-23**, **25** were synthesised according to the pathways reported in Scheme 1. The compounds **11-13** were obtained starting from the 3-bromopropoxy substituted benzaldehydes **5-7** which after treating with AgNO₃ in acetonitrile solution afforded the corresponding 3-nitrooxypropoxy analogues **8-10**. These latter intermediates treated with KMnO₄ in acetone solution gave the expected corresponding acids. *p*-Nitrooxypropyl substituted benzoic acid **18** was prepared starting from allylphenyl substituted dioxolane **15** which was transformed into alcohol **15a** by action of disiamylborane ((Sia)₂BH) and then of H₂O₂ in the presence of NaOH. **15a**, after partial purification, was immediately hydrolysed with 4M HCl to the aldehyde **16**. This intermediate was subjected to the action of *N*-bromosuccinimide (NBS) in acetonitrile solution in the presence of triphenylphosphine (Ph₃P) to gave **16a** that was immediately treated with AgNO₃ giving rise

to the aldehyde **17**. The related acid **18** was obtained following the same procedure used to prepare **11-13**. The compound **21** was synthesised from the corresponding bromo derivative **20** by action of AgNO_3 in acetonitrile solution. Acids **22** and **23** were prepared from **21** for *m*-chloroperbenzoic acid and H_2O_2 oxidation respectively. Acid **25** was prepared by action of I_2 and AgNO_3 in acetonitrile solution on 4-allylthiobenzoic acid (**24**).

Most of the NO-aspirins described in the present work, namely products **28-39**, and the intermediate **40** were prepared by action of the cesium salt of appropriate acid prepared in situ on chloromethyl 2-(acetyloxy)benzoate (**27**) in DMF solution (Scheme 2). The remaining products were obtained according to the pathways outlined in Scheme 3. Oxidation of **38** with *m*-chloroperbenzoic acid and oxone provided sulfoxide and sulfone models **41** and **42** respectively. The action of acetaldehyde on acetylsalicylic acid chloride **43** produced the adduct **44** that was coupled with acid **21** in DMF solution in the presence of Cs_2CO_3 to produce the final compound **45**. Nitration of intermediate **40** with 65% HNO_3 in the presence of acetic anhydride gave rise to the pyridine derivative **46**. Finally product **32** afforded **47** through HCl hydrolysis. This latter was used as a reference to follow the hydrolysis of **32** in human serum.

Hydrolysis Studies. The possible hydrolytic routes of (nitrooxyacyloxy) aspirin esters are reported in Scheme 4. In order for compounds to release a meaningful amount of aspirin the rate constant of the deacetylation k_2 must be slower than the hydrolytic constant k_1 . The stabilities of the target products were assessed by high-performance liquid chromatography (HPLC) in buffered solutions at pH 1.0 and 7.4 as well as in human serum. The results are reported in Table 1. After 3h of incubation in acid solution both the aliphatic and the aromatic NO-donor aspirins resulted unchanged for about 98% with the only exception of **46** containing the electron poor pyridine ring. This product was transformed slightly more extensively (unchanged 84%). A similar behaviour was observed at physiological pH but, in this case, in addition to **46** (unchanged for 60%) also **41** and **42**, containing the electron-withdrawing SO or SO_2 groups on the benzene ring, displayed less stability compared to the other terms of the series

(unchanged for 90% and for 70% respectively). Quite different results were obtained in serum in which the hydrolysis of a variety of esters is catalysed by carboxylesterases. These enzymes are ubiquitous and display a broad substrate specificity. Frequently the same ester can be hydrolysed by more than one of these enzymes.³¹ It was assumed that (acyloxy)alkyl esters are hydrolysed to the corresponding hydroxyalkyl esters which immediately and spontaneously decompose to the related carboxylic acids and aldehydes.²⁴ According to Scheme 4, aspirin, salicylates, nitrooxy-substituted carboxylic acids and salicylic acid were detected during the hydrolysis. The time-course of the metabolites detected over 10 min and 2h in the case of products **32** and **36**, is reported in Figure 1 and Figure 2 as examples. For all the products the final metabolites (6h) were salicylic acid and nitrooxy-substituted carboxylic acids. The hydrolysis strictly followed first order kinetics. The observed pseudo-first-order rate constants (k_{obs}) were calculated from the slopes of linear plots of the logarithm of the remaining ester against time: the corresponding half-lives were obtained from equation 1 (Table 1)

$$t_{1/2} = 0.693 / k_{obs} \text{ (Eq. 1)}$$

In Table 1 the maximal amounts of aspirin detected for each product, expressed as % of the initial ester concentration are also collected. Analyses of the data show that all the compounds are very quickly hydrolysed in serum. A number of products display $t_{1/2} < 1$ min and this figure does not exceed 5.4 min in the others. The peak of aspirin released in the aliphatic nitrooxyacyl series (**28-31**) ranges from 11% to 20%. The products of the aromatic series are definitively better aspirin releasing compounds. In the set of mononitrooxy-alkyloxy substituted models the release follows the series **33** > **34** >> **32**. The very low release of aspirin from the *o*-derivative is probably due to the negative effect of steric hindrance on hydrolysis exerted by the substituent group in proximity of the ester function. The dinitrooxy substituted compound **35** appears to be more susceptible to the enzymatic cleavage of acetyloxy group than the mononitrooxy structurally related **34**. All the other compounds we considered bear a *p*-substituent at the phenyl ring of benzoic acid. This is due to their easier synthetic availability, but the good results obtained with **33** indicates that the *m*-substitution could also be worthy of investigation. The products **36**

and **38**, bearing mononitrooxypropyl- and mononitrooxypropylthio- chains respectively, are among the best aspirin releasing products of the series. Moving to the dinitrooxy analogues **37** and **39** this capacity decreases. The change in the oxidation level of the sulphur chain of **38** affords the sulfoxide **41** and the sulfone **42** which are very good aspirin releasing compounds. As expected, the introduction of a methyl group on the methylene moiety of the acyloxymethyl substructure of **38** to give **45** weakens the production of aspirin, reasonably for steric reason. Finally, the good behaviour of the pyridine derivative **46** indicates that other interesting NO-donor aspirins could be designed from the use of other π -deficient heterocycle carboxylic acids.

Platelet Antiaggregatory Activity. Antiaggregatory effects of the new NO-aspirins were studied on collagen induced platelet aggregation of human platelet rich plasma (PRP), taking aspirin as a reference. The inhibitory activity of the compounds was tested by addition of product to PRP 10 min before addition of the stimulus. All the products displayed a concentration dependent inhibitory effect. Their antiaggregatory potency, expressed as IC_{50} , are reported in Table 1. By contrast no antiaggregatory activity was observed when the related nitrooxy substituted carboxylic acids, which are rapidly formed from the parent drugs under the action of plasma esterases, were tested at 300 μ M concentration. This finding is consistent with the known inability of platelets to efficiently effect NO-release from organic nitrates.³² As expected, the products of the aromatic series are definitively more active than the products of aliphatic series. The low activity of these latter compounds prevented us from determining their IC_{50} values. The areas under the aspirin release curves (AUC) of all the products, measured after 10 minutes of incubation, are reported in Table 1. In the aromatic series there is a rather good linear correlation ($r^2 = 0.8732$) between these values and the corresponding IC_{50} values (Figure 3), despite the different medium in which they were measured, serum and plasma respectively (equation 2, the standard error of regression coefficients is given within parentheses).

$$IC_{50} = -0.27 (\pm 0.03) AUC + 174 (\pm 12) \quad (\text{Eq. 2})$$

$$n = 11, r^2 = 0.8732, F = 61.98$$

Vasodilator Activities. The vasodilator activity of the new NO-donor aspirins was evaluated on endothelium denuded rat aorta strips precontracted with phenylephrine. The vasodilator action of the nitrooxy-substituted acids, intermediates in the synthesis of the target compounds and which are, together with salicylic acid, the final metabolites of the hydrolysis of these products, were assessed as well. As a nitrooxy-substituted acid for compound **46** we used 6-(nitrooxymethyl)pyridine-2-carboxylic acid (**48**). All the products were able to relax the contracted tissue in a concentration-dependent manner. Their potencies, expressed as EC₅₀, are collected in Table 2. The nitrooxy-substituted acids are always less potent than the parent compounds. The case of **36** and of the related acid **18** is reported in Figure 4 as an example. This is likely due to their greater hydrophilicity which limits the penetration into the vascular smooth muscle cell. When the experiments were repeated in the presence of 1 μM ODQ (1*H*-[1,2,4]oxadiazolo[4,3-*a*]quinoxalin-1-one), a decrease in the potencies was observed, in keeping with a NO-induced activation of the sGC as a mechanism which underlies the vasodilator effect.

Conclusions. We were able to develop a class of (nitrooxyacyloxy)methyl esters of aspirins which behave as true NO-donor aspirins. The aspirin release, evaluated in serum, follows a pseudo-first-order kinetic. The amount of aspirin released is strongly dependent on the nature of acyloxy moiety. The best results were obtained using aromatic nitrooxyacyloyl moieties. In the case of the benzoyl derivatives, the most active compounds are those bearing NO-donor chains at *p*- or at *m*-position. All the products display in vitro vasodilator activities included the nitrooxy-substituted acids formed following metabolism. The products here described are new improved examples of NO-donor aspirins containing nitrooxy groups. They could represent an improved alternative to the use of aspirin in a variety of clinical applications. Studies are in progress aimed at examining their oral and dermal delivery characteristics.

Experimental Section

Synthesis. ¹H and ¹³C-NMR spectra were recorded on a Bruker Avance 300 at 300 and 75 MHz

respectively, using SiMe₄ as the internal standard, the following abbreviations were used to indicate the peak multiplicity: s = singlet; d = doublet; t = triplet; qt = quartet; qi = quintet; m = multiplet; br s = broad signal. Low resolution mass spectra were recorded with a Finnigan-Mat TSQ-700. Melting points were determined with a capillary apparatus (Büchi 540). Flash column chromatography was performed on silica gel (Merck Kieselgel 60, 230-400 mesh ASTM); PE stands for 40-60 petroleum ether. The progress of the reactions was followed by thin layer chromatography (TLC) on 5 × 20 cm plates with a layer thickness of 0.25 mm. Anhydrous magnesium sulphate was used as the drying agent for the organic phases. Organic solvents were removed under vacuum at 30 °C. Preparative HPLC was performed on a Lichrospher C₁₈ column (250 × 25 mm, 10 μm) (Merck Darmstadt, Germany) with a Varian ProStar mod-210 with Varian UV detector mod-325. Elemental analyses (C, H, N) were performed by REDOX (Monza) and the results are within ± 0.4% of the theoretical values. Compounds **1**,²⁵ **2**,²⁶ **3**,²⁷ **4**,²⁸ **5**,³³ **6**,³³ **7**,³⁴ **14**,²⁹ **19**,²⁹ **20**,³⁵ **24**,³⁶ **26**,³⁰ **27**,³⁷ **43**,³⁸ **48**,³⁰ were synthesised according to literature. Compound **15** was synthesised with standard method³⁹ starting from 4-allylbenzaldehyde.²⁹

General procedure for the preparation of 8, 9, 10.

A solution of the appropriate bromo derivative (2.20 g, 9.05 mmol) and AgNO₃ (3.10 g, 18.10 mmol) in CH₃CN (25 mL) was stirred at 70 °C for 1h. Then brine was added to precipitate the excess of AgNO₃, the mixture was filtered through Celite and concentrated under reduced pressure. The residue was treated with CH₂Cl₂ (50 mL) and H₂O (50 mL). After separation the aqueous layer was extracted twice with CH₂Cl₂ (50 mL). The combined organic layers were dried, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography (PE/EtOAc 90/10 v/v) to give the compound as a pale yellow oil.

3-(2-Formylphenoxy)propyl nitrate (8): yield 70%. ¹H-NMR (CDCl₃) δ 2.31 (*qi*, 2H, -CH₂CH₂ONO₂), 4.20 (*t*, 2H, -OCH₂-, ³J_{HH} = 6.0 Hz), 4.71 (*t*, 2H, -CH₂ONO₂, ³J_{HH} = 6.0 Hz), 6.98 (*d*, 1H, C₆H₄), 7.06 (*t*, 1H, C₆H₄), 7.53-7.59 (*m*, 1H, C₆H₄), 7.82-7.85 (*m*, 1H, C₆H₄), 10.48 (*s*, 1H, -CHO).

^{13}C -NMR (CDCl_3) δ 27.0, 64.2, 69.6, 112.3, 121.2, 124.9, 128.8, 136.0, 160.6, 189.3. MS (CI) m/z 226 ($\text{M}+1$) $^+$.

3-(3-Formylphenoxy)propyl nitrate (9): yield 90%. ^1H -NMR (CDCl_3) δ 2.25 (*qi*, 2H, $-\text{CH}_2\text{CH}_2\text{ONO}_2$), 4.14 (*t*, 2H, $-\text{OCH}_2$, $^3J_{\text{HH}} = 6.0$ Hz), 4.69 (*t*, 2H, $-\text{CH}_2\text{ONO}_2$, $^3J_{\text{HH}} = 6.3$ Hz), 7.13-7.21 (*m*, 1H, C_6H_4), 7.38-7.50 (*m*, 3H, C_6H_4), 9.97 (*s*, 1H, $-\text{CHO}$). ^{13}C -NMR (CDCl_3) δ 26.9, 63.9, 69.8, 112.6, 121.8, 124.0, 130.2, 137.8, 159.0, 192.0. MS (CI) m/z 226 ($\text{M}+1$) $^+$.

3-(4-Formylphenoxy)propyl nitrate (10): yield 93%. ^1H -NMR (CDCl_3) δ 2.26 (*qi*, 2H, $-\text{CH}_2\text{CH}_2\text{ONO}_2$), 4.16 (*t*, 2H, $-\text{OCH}_2$, $^3J_{\text{HH}} = 6.0$ Hz), 4.69 (*t*, 2H, $-\text{CH}_2\text{ONO}_2$, $^3J_{\text{HH}} = 6.3$ Hz), 7.00 (*d*, 2H, C_6H_4), 7.84 (*d*, 2H, C_6H_4), 9.89 (*s*, 1H, $-\text{CHO}$). ^{13}C -NMR (CDCl_3) δ 26.9, 64.0, 69.7, 115.2, 130.3, 132.0, 163.4, 190.8. MS (CI) m/z 226 ($\text{M}+1$) $^+$.

3-(4-Formylphenyl)propyl nitrate (17):

A solution of NaBH_4 (11.3 g, 0.30 mol) in dry THF (250 mL) was slowly added to amylene (115 mL, 1.1 mol) stirred at 0 °C. Then $\text{BF}_3 \cdot \text{Et}_2\text{O}$ (27.5 mL, 0.22 mol) was added in 30 min to the mixture maintained at 0 °C. After 5.5 hours a solution of **15** (4.20 g, 22.1 mmol) in dry THF (100 mL) was slowly added and the stirring was continued for 24 hours. Then to the mixture, cooled at 0 °C, H_2O (140 mL), NaOH 3M (140 mL) and H_2O_2 30% (210 mL) were added and the resulting mixture was heated at 40 °C for 1.5 hours. After separation the organic layer was washed with H_2O (100 mL), dried, filtered and concentrated under reduced pressure. The crude product so obtained was purified by flash chromatography (PE/EtOAc 8/2 to 6/4 v/v) to give 3-[4-(1,3-dioxolan-2-yl)phenyl]propan-1-ol (**15a**) as a colourless oil. 4M HCl (20 mL) was added to a stirred solution **15a** (4.50 g, 21.61 mmol) in MeOH/ H_2O 1/1 (90 mL). After 2 hours the reaction was completed; the mixture was concentrated under reduced pressure and extracted twice with CH_2Cl_2 (50 mL). The combined organic layers were washed with brine (20 mL), dried, filtered and concentrated under reduced pressure to give **16** as a pale yellow oil. Yield 97%.

NBS (4.49 g, 25.21 mmol) was added portionwise to a solution of **16** (3.45 g, 21.01 mmol) and Ph₃P (6.06 g, 23.11 mmol) in dry CH₃CN (50 mL), stirred at 0 °C. After 30 min the reaction was completed, the mixture was diluted with CH₂Cl₂ (50 mL), washed twice with H₂O (50 mL), dried, filtered and concentrated under reduced pressure. AgNO₃ (7.14 g; 42.02 mmol) was added to a solution of the crude in CH₃CN (50 mL) and the mixture was heated at 70 °C for 1h. Then brine was added to precipitate the excess of AgNO₃, the mixture was filtered through Celite, the residue was diluted with CH₂Cl₂ (50 mL) and washed with H₂O (50 mL). The organic layer was dried, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography (PE/EtOAc 80/20 v/v) to give the title compound as a pale yellow oil. Yield 76%. ¹H-NMR (CDCl₃) δ 2.04-2.14 (*m*, 2H, -CH₂CH₂ONO₂), 2.83 (*t*, 2H, -CH₂-, ³J_{HH} = 7.5 Hz), 4.47 (*t*, 2H, -CH₂ONO₂, ³J_{HH} = 6.6 Hz), 7.36 (*d*, 2H, C₆H₄), 7.83 (*d*, 2H, C₆H₄), 9.99 (*s*, 1H, -CHO). ¹³C-NMR (CDCl₃) δ 28.3, 32.3, 72.3, 129.4, 130.5, 135.3, 147.8, 192.2. MS (CI) *m/z* 210 (M+1)⁺.

General procedure for the preparation of 11, 12, 13, 18.

KMnO₄ (2.00 g, 12.58 mmol) was added to a solution of the appropriate aldehyde (1.89 g, 8.39 mmol) in acetone (25 mL), stirred at 0 °C. The reaction was allowed to reach r.t. and it was completed after 1h. Oxalic acid was added until the colour of the mixture became green, then the mixture was filtered and the filtrate was diluted with CH₂Cl₂ (50 mL). The organic layer was washed with H₂O (50 mL), then dried, filtered and concentrated under reduced pressure.

2-[3-(Nitrooxy)propoxy]benzoic acid (11): the crude product so obtained was purified by flash chromatography (PE/EtOAc/HCOOH 90/10/0.1 v/v/v) to give the title compound as a colourless oil; yield 47%. ¹H-NMR (CDCl₃) δ 2.34 (*qi*, 2H, -CH₂CH₂ONO₂), 4.30 (*t*, 2H, -OCH₂-, ³J_{HH} = 6.0 Hz), 4.73 (*t*, 2H, -CH₂ONO₂, ³J_{HH} = 6.0 Hz), 7.03 (*d*, 1H, C₆H₄), 7.11 (*t*, 1H, C₆H₄), 7.53-7.59 (*m*, 1H, C₆H₄), 8.09-8.12 (*m*, 1H, C₆H₄), 11.0 (*br s*, 1H, -COOH). ¹³C-NMR (CDCl₃) δ 26.9, 65.5, 69.5, 112.8, 118.3, 121.9, 133.6, 135.0, 157.8, 167.7. MS (CI) *m/z* 242 (M+1)⁺.

3-[3-(Nitrooxy)propoxy]benzoic acid (12): m.p. 110-111 °C (from *i*Pr₂O); white solid; yield

75%. ¹H-NMR (DMSO-d₆) δ 2.16 (*qi*, 2H, -CH₂CH₂ONO₂), 4.12 (*t*, 2H, -OCH₂-), 4.70 (*t*, 2H, -CH₂ONO₂), 7.19-7.21 (*m*, 1H, C₆H₄), 7.40-7.71 (*m*, 3H, C₆H₄), 13.0 (*br s*, 1H, -COOH). ¹³C-NMR (DMSO-d₆) δ 26.6, 64.6, 71.3, 114.9, 119.7, 122.2, 130.1, 132.6, 158.7, 167.5. MS (CI) *m/z* 242 (M+1)⁺.

4-[3-(Nitrooxy)propoxy]benzoic acid (13): m.p. 137-138 °C (from *i*Pr₂O/*i*PrOH); white solid; yield 81%. ¹H-NMR (DMSO-d₆) δ 2.20 (*qi*, 2H, -CH₂CH₂ONO₂), 4.18 (*t*, 2H, -OCH₂-, ³J_{HH} = 6.0 Hz), 4.73 (*t*, 2H, -CH₂ONO₂, ³J_{HH} = 6.3 Hz), 7.05 (*d*, 2H, C₆H₄), 7.93 (*d*, 2H, C₆H₄), 12.7 (*s*, 1H, -COOH). ¹³C-NMR (DMSO-d₆) δ 26.5, 64.7, 71.3, 114.6, 123.5, 131.8, 162.3, 167.4. MS (CI) *m/z* 242 (M+1)⁺.

4-[3-(Nitrooxy)propyl]benzoic acid (18): m.p. 125.5-126.5 °C (from *i*Pr₂O); white solid; yield 89%. ¹H-NMR (CDCl₃) δ 2.09 (*qi*, 2H, -CH₂CH₂ONO₂), 2.82 (*t*, 2H, C₆H₄CH₂-, ³J_{HH} = 7.5 Hz), 4.46 (*t*, 2H, -CH₂ONO₂, ³J_{HH} = 6.3 Hz), 7.30 (*d*, 2H, C₆H₄), 8.06 (*d*, 2H, C₆H₄), 11.7 (*br s*, 1H, -COOH). ¹³C-NMR (CDCl₃) δ 28.0, 31.9, 72.0, 127.6, 128.6, 130.7, 146.7, 171.9. MS (CI) *m/z* 226 (M+1)⁺.

4-[3-(Nitrooxy)propylthio]benzoic acid (21).

A solution of **20** (2.70 g, 10.0 mmol) and AgNO₃ (3.40 g, 20.0 mmol) in CH₃CN (50 mL) was stirred at 70 °C for 5h. Then brine was added to precipitate the excess of AgNO₃, the mixture was filtered through Celite and concentrated under reduced pressure. The residue was treated with CH₂Cl₂ (50 mL) and H₂O (50 mL). After separation the aqueous layer was extracted twice with CH₂Cl₂ (50 mL). The combined organic layers were dried, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography (PE/EtOAc/HCOOH 80/20/0.1 v/v/v) to give the title compound as a white solid. Yield 80%. M.p. 103.5-105.5 °C (from *i*Pr₂O/*i*PrOH). ¹H-NMR (CD₃OD) δ 2.07 (*qi*, 2H, -CH₂CH₂ONO₂), 3.13 (*t*, 2H, -SCH₂-, ³J_{HH} = 7.2 Hz), 4.60 (*t*, 2H, -CH₂ONO₂, ³J_{HH} = 6.3 Hz), 7.38 (*d*, 2H, C₆H₄), 7.93 (*d*, 2H, C₆H₄). ¹³C-NMR (CD₃OD) δ 27.4, 28.9, 72.8, 127.9, 128.8, 131.3, 144.4, 169.4. MS (CI) *m/z* 258 (M+1)⁺.

4-[3-(Nitrooxy)propyl-1-sulfinyl]benzoic acid (22).

A solution of 70% mCPBA (0.25 g, 1.0 mmol) in dry CH₂Cl₂ (10 mL) was slowly added to a solution

of **21** (0.26 g, 1.0 mmol) in dry CH₂Cl₂ (15 mL), stirred at -78 °C. At the end of the addition the reaction was completed. The mixture was poured in 10% Na₂SO₃ (50 mL), the layers separated and the aqueous layer was extracted twice with Et₂O (50 mL). The organic layers were dried, filtered and concentrated under reduced pressure. The crude product so obtained was purified by flash chromatography (PE/EtOAc/HCOOH 80/20/0.1 v/v/v) to give the title compound as a white solid. Yield 55%. M.p. 154.5-155.0 °C. ¹H-NMR (DMSO-d₆) δ 1.70-1.90 (*m*, 1H, -CH_aH_bCH₂ONO₂), 2.00-2.14 (*m*, 1H, -CH_aH_bCH₂ONO₂), 2.86-2.95 (*m*, 1H, SOCH_aH_b-), 3.15-3.35 (*m*, 1H, SOCH_aH_b-), 4.58 (*t*, 2H, -CH₂ONO₂, ³J_{HH} = 6.3 Hz), 7.80 (*d*, 2H, C₆H₄), 8.12 (*d*, 2H, C₆H₄), 13.32 (*br s*, 1H, COOH). ¹³C-NMR (DMSO-d₆) δ 19.7, 51.7, 73.0, 125.1, 131.1, 133.7, 149.4, 167.4. MS (CI) *m/z* 274 (M+1)⁺.

4-[3-(Nitrooxy)propyl-1-sulfonyl]benzoic acid (23).

A solution of 85% H₂O₂ (0.31 g, 7.76 mmol) in CF₃COOH (2 mL) was slowly added to a suspension of **21** (0.50 g, 1.94 mmol) in CF₃COOH (5 mL) stirred at 0 °C. The reaction was allowed to reach r.t. and it was completed after 1.5h. The mixture was poured into ice/water and the white solid so obtained was filtered. The crude product was purified by flash chromatography (CH₂Cl₂/EtOAc/HCOOH 95/5/0.1 v/v/v) to give the title compound as a white solid. Yield 74%. M.p. 172-173.5 °C. ¹H-NMR (DMSO-d₆) δ 1.97 (*qi*, 2H, -CH₂CH₂ONO₂), 3.51 (*t*, 2H, SO₂CH₂CH₂-, ³J_{HH} = 7.5 Hz), 4.56 (*t*, 2H, -CH₂ONO₂, ³J_{HH} = 6.3 Hz), 8.04 (*d*, 2H, C₆H₄), 8.19 (*d*, 2H, C₆H₄), 13.6 (*br s*, 1H, COOH). ¹³C-NMR (DMSO-d₆) δ 20.1, 50.9, 71.2, 128.1, 130.1, 135.5, 142.0, 166.0. MS (CI) *m/z* 290 (M+1)⁺.

4-[[2,3-Bis(nitrooxy)propyl]thio]benzoic acid (25)

Iodine (8.2 g, 32.38 mmol) was added portionwise to a stirred solution of **24** (6.30 g, 32.38 mmol) and AgNO₃ (5.50 g, 32.38 mmol) in CH₃CN (100 mL) kept at -15 °C. At the end of the addition the stirring was continued for 1h. Then AgNO₃ (11.0 g, 64.76 mmol) was added and the mixture was heated at 70 °C for 16h. After cooling the mixture was filtered through Celite. The filtrate was concentrated under reduced pressure, dissolved in water (50 mL) and extracted with CH₂Cl₂ (3 × 100 mL). The combined organic layers were washed with brine (50 mL), dried, filtered and concentrated under reduced pressure.

The crude product was purified by flash chromatography (PE/EtOAc/HCOOH 80/20/0.1 v/v/v) to give the title compound as white solid. Yield 60%. M.p. 132-133 °C (toluene). ¹H-NMR (DMSO-d₆) δ 3.50-3.63 (*m*, 2H, -SCH₂-), 4.77-4.86 (*m*, 1H, -CH_aH_bONO₂), 5.00-5.05 (*m*, 1H, -CH_aH_bONO₂), 5.52-5.58 (*m*, 1H, -CH(ONO₂-)), 7.53 (*d*, 2H, C₆H₄), 7.87 (*d*, 2H, C₆H₄), 13.00 (*br s*, 1H, -COOH). ¹³C-NMR (DMSO-d₆) δ 30.5, 71.3, 78.6, 127.8, 128.7, 130.5, 141.1, 167.2. MS (CI) *m/z* 319 (M+1)⁺.

General procedure for the preparation of 28-40.

To a solution of the appropriate carboxylic acid (1.00 mmol) in DMF (5 mL) were added Cs₂CO₃ (0.50 mmol) and after 10 min **27** (1.00 mmol). The mixture was stirred for 24 hours, then poured in H₂O (10 mL) and extracted with Et₂O (3 × 10 mL). The combined organic layers were washed with a saturated solution of NaHCO₃ (10 mL), dried, filtered and concentrated under reduced pressure. The crude product so obtained was purified by flash chromatography. Chromatographic eluents and yields of the products were as follow.

{[6-(Nitrooxy)hexanoyl]oxy}methyl 2-(acetyloxy)benzoate (28): eluent (PE/EtOAc 9/1 v/v); colourless oil; yield 70%. ¹H-NMR (CDCl₃) δ 1.41-1.49 (*m*, 2H), 1.64-1.78 (*m*, 4H) (-CH₂CH₂CH₂CH₂ONO₂), 2.36 (*s*, 3H, CH₃COO-), 2.41 (*t*, 2H, -OCOCH₂-, ³J_{HH} = 7.2 Hz), 4.41 (*t*, 2H, -CH₂ONO₂, ³J_{HH} = 6.6 Hz), 5.95 (*s*, 2H, -OCH₂O-), 7.12 (*d*, 1H, C₆H₄), 7.33 (*t*, 1H, C₆H₄), 7.61 (*t*, 1H, C₆H₄), 8.07 (*d*, 1H, C₆H₄). ¹³C-NMR (CDCl₃) δ 21.2, 24.3, 25.3, 26.7, 33.8, 73.1, 79.4, 122.2, 124.3, 126.4, 132.4, 135.0, 151.4, 163.2, 169.9, 172.2. MS (CI) *m/z* 370 (M+1)⁺.

{[5,6-Bis(nitrooxy)hexanoyl]oxy}methyl 2-(acetyloxy)benzoate (29): eluent (PE/EtOAc 8/2 v/v); colourless oil; yield 36%. ¹H-NMR (CDCl₃) δ 1.74-1.83 (*m*, 4H, -CH₂CH₂CH-), 2.36 (*s*, 3H, CH₃COO-), 2.45-2.48 (*m*, 2H, -OCOCH₂-), 4.39-4.46 (*m*, 1H, -CH_aH_bONO₂), 4.68-4.74 (*m*, 1H, -CH_aH_bONO₂), 5.25-5.28 (*m*, 1H, -CHONO₂-), 5.95 (*s*, 2H, -OCH₂O-), 7.12 (*d*, 1H, C₆H₄), 7.34 (*t*, 1H, C₆H₄), 7.61 (*t*, 1H, C₆H₄), 8.08 (*d*, 1H, C₆H₄). ¹³C-NMR (CDCl₃) δ 20.0, 21.0, 28.4, 33.0, 71.0, 78.7, 79.2, 121.8, 124.0, 126.2, 132.2, 134.9, 151.1, 163.0, 169.6, 171.3. MS (CI) *m/z* 431 (M+1)⁺.

{[7-(Nitrooxy)heptanoyl]oxy}methyl 2-(acetyloxy)benzoate (30): eluent (PE/EtOAc 8/2 v/v); colourless oil; yield 52%. $^1\text{H-NMR}$ (CDCl_3) δ 1.34-1.43 (*m*, 4H), 1.61-1.71 (*m*, 4H) ($-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{ONO}_2$), 2.36-2.42 (*m*, 5H, $\text{CH}_3\text{COO-}$ + $-\text{OCOCH}_2-$), 4.41 (*t*, 2H, $-\text{CH}_2\text{ONO}_2$, $^3J_{\text{HH}} = 6.6$ Hz), 5.94 (*s*, 2H, $-\text{OCH}_2\text{O-}$), 7.12 (*d*, 1H, C_6H_4), 7.33 (*t*, 1H, C_6H_4), 7.61 (*t*, 1H, C_6H_4), 8.07 (*d*, 1H, C_6H_4). $^{13}\text{C-NMR}$ (CDCl_3) δ 21.0, 24.3, 25.3, 26.5, 28.4, 33.7, 73.2, 79.2, 122.0, 124.1, 126.2, 132.2, 134.7, 151.2, 163.0, 169.7, 171.1. MS (CI) m/z 384 ($\text{M}+1$) $^+$.

{[6,7-Bis(nitrooxy)heptanoyl]oxy}methyl 2-(acetyloxy)benzoate (31): the crude product was purified partially by flash chromatography (PE/EtOAc 8/2 v/v) and then by RP18 preparative HPLC (flow 39 mL/min, λ 226 nm, $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ 65/35 v/v, injection 2 mL, solution 100 mg/mL); colourless oil; yield 30%. $^1\text{H-NMR}$ (CDCl_3) δ 1.45-1.51 (*m*, 2H), 1.65-1.76 (*m*, 4H) ($-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH-}$), 2.35 (*s*, 3H, $\text{CH}_3\text{COO-}$), 2.42 (*t*, 2H, $-\text{OCOCH}_2-$, $^3J_{\text{HH}} = 6.9$ Hz), 4.38-4.45 (*m*, 1H, $-\text{CH}_a\text{H}_b\text{ONO}_2$), 4.67-4.72 (*m*, 1H, $-\text{CH}_a\text{H}_b\text{ONO}_2$), 5.15-5.28 (*m*, 1H, $-\text{CHONO}_2-$), 5.95 (*s*, 2H, $-\text{OCH}_2\text{O-}$), 7.12 (*d*, 1H, C_6H_4), 7.34 (*t*, 1H, C_6H_4), 7.60 (*t*, 1H, C_6H_4), 8.08 (*d*, 1H, C_6H_4). $^{13}\text{C-NMR}$ (CDCl_3) δ 20.9, 24.0, 24.2, 29.0, 33.4, 71.1, 78.9, 79.2, 121.9, 124.1, 126.2, 132.2, 134.8, 151.1, 163.0, 169.7, 171.8. MS (CI) m/z 445 ($\text{M}+1$) $^+$.

{[2-[3-(Nitrooxy)propoxy]benzoyl]oxy}methyl 2-(acetyloxy)benzoate (32): eluent (PE/EtOAc 90/10 v/v); colourless oil; yield 73%. $^1\text{H-NMR}$ (CDCl_3) δ 2.21 (*qi*, 2H, $-\text{CH}_2\text{CH}_2\text{ONO}_2$), 2.36 (*s*, 3H, $\text{CH}_3\text{COO-}$), 4.12 (*t*, 2H, $-\text{OCH}_2\text{CH}_2-$, $^3J_{\text{HH}} = 5.7$ Hz), 4.72 (*t*, 2H, $-\text{CH}_2\text{ONO}_2$, $^3J_{\text{HH}} = 6.3$ Hz), 6.16 (*s*, 2H, $-\text{OCH}_2\text{O-}$), 6.94 (*d*, 1H, C_6H_4), 7.01 (*t*, 1H, C_6H_4), 7.12 (*d*, 1H, C_6H_4), 7.33 (*t*, 1H, C_6H_4), 7.50 (*t*, 1H, C_6H_4), 7.60 (*t*, 1H, C_6H_4), 7.91 (*d*, 1H, C_6H_4), 8.11 (*d*, 1H, C_6H_4). $^{13}\text{C-NMR}$ (CDCl_3) 20.9, 26.9, 64.3, 69.9, 79.5, 113.1, 118.6, 120.7, 122.0, 124.0, 126.2, 132.3, 132.6, 134.6, 134.7, 151.2, 158.7, 163.1, 164.4, 169.7. MS (CI) m/z 434 ($\text{M}+1$) $^+$.

{[3-[3-(Nitrooxy)propoxy]benzoyl]oxy}methyl 2-(acetyloxy)benzoate (33): eluent (PE/EtOAc 90/10 v/v); colourless oil; yield 65%. $^1\text{H-NMR}$ (CDCl_3) δ 2.23 (*qi*, 2H, $-\text{CH}_2\text{CH}_2\text{ONO}_2$), 2.36 (*s*, 3H, $\text{CH}_3\text{COO-}$), 4.12 (*t*, 2H, $-\text{OCH}_2\text{CH}_2-$, $^3J_{\text{HH}} = 6.0$ Hz), 4.67 (*t*, 2H, $-\text{CH}_2\text{ONO}_2$, $^3J_{\text{HH}} = 6.3$ Hz), 6.19 (*s*, 2H, $-\text{OCH}_2\text{O-}$), 7.12 (*d*, 2H, C_6H_4), 7.30-7.40 (*m*, 2H, C_6H_4), 7.58-7.73 (*m*, 2H, C_6H_4), 7.71 (*d*, 1H,

C₆H₄), 8.09 (*d*, 1H, C₆H₄). ¹³C-NMR (CDCl₃) 21.0, 26.9, 63.8, 69.8, 79.9, 114.9, 120.7, 122.0, 123.0, 124.0, 126.2, 129.7, 130.2, 132.3, 134.7, 151.1, 158.5, 163.0, 165.0, 169.7. MS (CI) *m/z* 434 (M+1)⁺.

({4-[3-(Nitrooxy)propoxy]benzoyl}oxy)methyl 2-(acetyloxy)benzoate (34): eluent (PE/EtOAc 8/2 v/v); colourless oil; yield 47%. ¹H-NMR (CDCl₃) δ 2.23 (*qi*, 2H, -CH₂CH₂ONO₂), 2.35 (*s*, 3H, CH₃COO-), 4.12 (*t*, 2H, -OCH₂CH₂-, ³J_{HH} = 5.7 Hz), 4.66 (*t*, 2H, -CH₂ONO₂), 6.17 (*s*, 2H, -OCH₂O-), 6.91 (*d*, 2H, C₆H₄), 7.11 (*d*, 1H, C₆H₄), 7.32 (*t*, 1H, C₆H₄), 7.59 (*t*, 1H, C₆H₄), 8.03-8.10 (*m*, 3H, C₆H₄). ¹³C-NMR (CDCl₃) δ 21.0, 26.8, 63.8, 69.6, 79.8, 114.2, 121.6, 122.1, 124.0, 126.1, 132.3, 132.3, 134.6, 151.1, 162.8, 163.2, 164.8, 169.7. MS (CI) *m/z* 434 (M+1)⁺.

({4-[2,3-Bis(nitrooxy)propoxy]benzoyl}oxy)methyl 2-(acetyloxy)benzoate (35): eluent (PE/EtOAc 8/2 v/v); colourless oil; yield 37%. ¹H-NMR (CDCl₃) δ 2.36 (*s*, 3H, CH₃COO-), 4.31 (*d*, 2H, -OCH₂CH-³J_{HH} = 5.4 Hz), 4.75-4.81 (*m*, 1H, -CH_aH_bONO₂), 4.90-4.96 (*m*, 1H, -CH_aH_bONO₂), 5.61-5.64 (*m*, 1H, -CHONO₂-), 6.17 (*s*, 2H, -OCH₂O-), 6.94 (*d*, 2H, C₆H₄), 7.11 (*d*, 1H, C₆H₄), 7.32 (*t*, 1H, C₆H₄), 7.59 (*t*, 1H, C₆H₄), 8.05-8.09 (*m*, 3H, C₆H₄). ¹³C-NMR (CDCl₃) δ 20.9, 64.7, 68.6, 76.4, 79.8, 114.2, 122.0, 122.7, 124.0, 126.1, 132.2, 132.4, 134.7, 151.0, 161.6, 163.1, 164.6, 169.7. MS (CI) *m/z* 495 (M+1)⁺.

({4-[3-(Nitrooxy)propyl]benzoyl}oxy)methyl 2-(acetyloxy)benzoate (36): eluent (PE/EtOAc 9/1 v/v); colourless oil; yield 52%. ¹H-NMR (CDCl₃) δ 2.07 (*qi*, 2H, -CH₂CH₂ONO₂), 2.36 (*s*, 3H, CH₃COO-), 2.80 (*t*, 2H, -CH₂CH₂CH₂-, ³J_{HH} = 7.2 Hz), 4.44 (*t*, 2H, -CH₂ONO₂, ³J_{HH} = 6.3 Hz), 6.19 (*s*, 2H, -OCH₂O-), 7.12 (*d*, 1H, C₆H₄), 7.26-7.35 (*m*, 3H, C₆H₄), 7.59 (*t*, 1H, C₆H₄), 8.02-8.11 (*m*, 3H, C₆H₄). ¹³C-NMR (CDCl₃) δ 21.0, 28.0, 31.8, 72.0, 79.7, 122.0, 124.0, 126.1, 127.1, 128.6, 130.5, 132.3, 134.7, 146.6, 151.1, 163.1, 165.0, 169.7. MS (CI) *m/z* 418 (M+1)⁺.

({4-[2,3-Bis(nitrooxy)propyl]benzoyl}oxy)methyl 2-(acetyloxy)benzoate (37): eluent (PE/EtOAc 8/2 v/v); colourless oil; yield 60%. ¹H-NMR (CDCl₃) δ 2.35 (*s*, 3H, CH₃COO-), 3.03-3.18 (*m*, 2H, -CH₂CH-), 4.40-4.46 (*m*, 1H, -CH_aH_bONO₂), 4.70-4.75 (*m*, 1H, -CH_aH_bONO₂), 5.42-5.50 (*m*, 1H, -CHONO₂-), 6.19 (*s*, 2H, -OCH₂O-), 7.12 (*d*, 1H, C₆H₄), 7.26-7.35 (*m*, 3H, C₆H₄), 7.59 (*t*, 1H, C₆H₄), 8.06-8.10 (*m*, 3H, C₆H₄). ¹³C-NMR (CDCl₃) δ 21.0, 35.6, 60.4, 70.1, 78.7, 124.5, 126.4, 128.2, 129.9,

131.3, 132.2, 135.6, 141.4, 151.9, 159.6, 161.6, 169.5, 171.2. MS (CI) m/z 479 (M+1)⁺.

[(4-{[3-(Nitrooxy)propyl]thio}benzoyl)oxy]methyl 2-(acetyloxy)benzoate (38): eluent (PE/EtOAc 9/1 v/v); colourless oil that became solid on standing; yield 70%. ¹H-NMR (CDCl₃) δ 2.10 (*qi*, 2H, -CH₂CH₂ONO₂), 2.35 (*s*, 3H, CH₃COO-), 3.09 (*t*, 2H, -SCH₂CH₂-, ³J_{HH} = 7.9 Hz), 4.57 (*t*, 2H, -CH₂ONO₂, ³J_{HH} = 6.3 Hz), 6.18 (*s*, 2H, -OCH₂O-), 7.12 (*d*, 1H, C₆H₄), 7.30-7.34 (*m*, 3H, C₆H₄), 7.59 (*t*, 1H, C₆H₄), 7.99 (*d*, 2H, C₆H₄), 8.08 (*d*, 1H, C₆H₄). ¹³C-NMR (CDCl₃) δ 21.0, 26.1, 28.1, 71.0, 79.8, 122.0, 124.0, 125.9, 126.1, 126.9, 130.6, 132.3, 134.7, 143.7, 151.1, 163.1, 164.8, 169.7. MS (CI) m/z 450 (M+1)⁺.

[(4-{[2,3-Bis(nitrooxy)propyl]thio}benzoyl)oxy]methyl 2-(acetyloxy)benzoate (39): eluent (PE/EtOAc 8/2 v/v); colourless oil; yield 36%. ¹H-NMR (CDCl₃) δ 2.36 (*s*, 3H, CH₃COO-), 3.20-3.28 (*m*, 1H, -SCH_aH_b-), 3.35-3.42 (*m*, 1H, -SCH_aH_b-), 4.63-4.69 (*m*, 1H, -CH_aH_bONO₂), 4.86-4.91 (*m*, 1H, -CH_aH_bONO₂), 5.28-5.36 (*m*, 1H, -CHONO₂-), 6.19 (*s*, 2H, -OCH₂O-), 7.12 (*d*, 1H, C₆H₄), 7.33 (*t*, 1H, C₆H₄), 7.42 (*d*, 2H, C₆H₄), 7.60 (*t*, 1H, C₆H₄), 8.03-8.11 (*m*, 3H, C₆H₄). ¹³C-NMR (CDCl₃) δ 21.0, 31.4, 69.3, 77.2, 79.9, 122.0, 124.0, 126.2, 127.4, 128.3, 131.0, 132.3, 134.7, 141.1, 151.1, 163.0, 164.5, 169.7. MS (CI) m/z 511 (M+1)⁺.

{[2-(Acetyloxy)benzoyl]oxy}methyl 6-(hydroxymethyl)pyridine-2-carboxylate (40): eluent (CH₂Cl₂/EtOAc 9/1 v/v); pale yellow oil; yield 17%. ¹H-NMR (CDCl₃) δ 2.26 (*s*, 3H, CH₃COO-), 3.55 (*br s*, 1H, -CH₂OH), 4.75 (*s*, 2H, -CH₂OH), 6.14 (*s*, 2H, -OCH₂O-), 7.02 (*d*, 1H, C₆H₄), 7.22 (*t*, 1H, C₆H₄), 7.48-7.52 (*m*, 2H, C₆H₄ + C₅H₃N), 7.74 (*t*, 1H, C₆H₄), 7.90-8.00 (*m*, 2H, C₅H₃N). ¹³C-NMR (CDCl₃) δ 19.9, 63.5, 79.4, 120.8, 123.0, 123.4, 123.8, 125.2, 131.2, 133.8, 136.9, 144.6, 150.1, 160.0, 161.9, 162.6, 168.8. MS (CI) m/z 346 (M+1)⁺.

[(4-{[3-(Nitrooxy)propyl]sulfinyl}benzoyl)oxy]methyl 2-(acetyloxy)benzoate (41).

A solution of 70% mCPBA (0.25 g, 1.0 mmol) in dry CH₂Cl₂ (7 mL) was slowly added to a solution of **38** (0.45 g, 1.0 mmol) in dry CH₂Cl₂ (7 mL), stirred at -78 °C. At the end of the addition the reaction was completed. The mixture was poured in 10% Na₂SO₃ (50 mL), the layers separated and the aqueous

layer was extracted twice with Et₂O (50 mL). The organic layers were dried, filtered and concentrated under reduced pressure. The crude product so obtained was purified by flash chromatography (PE/EtOAc 6/4 v/v) to give the title compound as a colourless oil. Yield 73%. ¹H-NMR (CDCl₃) δ 1.97-2.05 (*m*, 1H, -SOCH₂CH_aH_b-), 2.23-2.33 (*m*, 1H, -SOCH₂CH_aH_b-), 2.37 (*s*, 3H, CH₃COO-), 2.76-2.85 (*m*, 1H, -SOCH_aH_b-), 2.98-3.07 (*m*, 1H, -SOCH_aH_b-), 4.52-4.58 (*m*, 2H, -CH₂ONO₂), 6.21 (*s*, 2H, -OCH₂O-), 7.13 (*d*, 1H, C₆H₄), 7.33 (*t*, 1H, C₆H₄), 7.61 (*t*, 1H, C₆H₄), 7.70 (*d*, 2H, C₆H₄), 8.10 (*d*, 1H, C₆H₄), 8.26 (*d*, 2H, C₆H₄). ¹³C-NMR (CDCl₃) δ 19.7, 21.0, 52.3, 71.1, 79.9, 121.8, 124.1, 124.1, 126.2, 131.0, 131.6, 132.2, 134.9, 149.1, 151.2, 162.9, 164.2, 169.7. MS (CI) m/z 466 (M+1)⁺.

[(4-{3-(Nitrooxy)propyl)sulfonyl}benzoyl)oxy]methyl 2-(acetyloxy)benzoate (42).

Oxone (0.40 g, 0.55 mmol) was added to a stirred solution of **38** (0.10 g, 0.22 mmol) in MeOH (3 mL) and H₂O (1 mL). 2h later the reaction was completed, the mixture was diluted with H₂O (10 mL) and extracted with CH₂Cl₂ (3 × 10 mL). The combined organic layers were dried, filtered and concentrated under reduced pressure. The crude product so obtained was purified by flash chromatography (PE/EtOAc 8/2 v/v) to give the title compound as a colourless oil. Yield 88%. ¹H-NMR (CDCl₃) δ 2.20 (*qi*, 2H, -CH₂CH₂ONO₂), 2.36 (*s*, 3H, CH₃COO-), 3.21 (*t*, 2H, -SO₂CH₂CH₂-, ³J_{HH} = 7.2 Hz), 4.56 (*t*, 2H, -CH₂ONO₂, ³J_{HH} = 6.3 Hz), 6.22 (*s*, 2H, -OCH₂O-), 7.13 (*d*, 1H, C₆H₄), 7.34 (*t*, 1H, C₆H₄), 7.61 (*t*, 1H, C₆H₄), 8.01 (*d*, 2H, C₆H₄), 8.10 (*d*, 1H, C₆H₄), 8.29 (*d*, 2H, C₆H₄). ¹³C-NMR (CDCl₃) δ 20.6, 21.0, 52.3, 70.2, 80.1, 121.7, 124.1, 126.2, 128.3, 131.1, 132.2, 134.0, 135.0, 143.1, 151.2, 162.9, 163.6, 169.7. MS (CI) m/z 482 (M+1)⁺.

1-Chloroethyl 2-(acetyloxy)benzoate (44).

To a solution of **43** (10.0 g, 50.35 mmol) in dry CH₂Cl₂ (100 mL) stirred under N₂ at room temperature dry ZnCl₂ (0.14 g) was added. After 15 min the reaction mixture was cooled at -15 °C and a solution of CH₃CHO (2.80 mL, 50.35 mmol) in dry CH₂Cl₂ (30 mL) was slowly added. The reaction mixture was allowed to reach room temperature and was stirred for 48h. Then it was washed with H₂O (100 mL) and a saturated solution of NaHCO₃ (100 mL), dried, filtered and concentrated under reduced

pressure. The crude product was purified by flash chromatography (PE/EtOAc 90/10 v/v) to give the title compound as a colourless oil that became solid on standing. Yield 64%. M.p. 42.5-45.5 °C. ¹H-NMR (CDCl₃) δ 1.89 (*d*, 3H, CH₃CH-, ³J_{HH} = 6.0 Hz), 2.36 (*s*, 3H, CH₃COO-), 6.73 (*q*, 1H, CH₃CH-, ³J_{HH} = 6.0 Hz), 7.13 (*d*, 1H, C₆H₄), 7.33 (*t*, 1H, C₆H₄), 7.59 (*t*, 1H, C₆H₄), 8.03 (*d*, 1H, C₆H₄). ¹³C-NMR (CDCl₃) δ 21.0, 25.3, 81.1, 122.0, 124.0, 126.1, 131.9, 134.7, 151.0, 162.0, 169.5. MS (CI) *m/z* 243/245 (M+1)⁺.

1-[(4-{[3-(Nitrooxy)propyl]thio}benzoyl)oxy]ethyl 2-(acetyloxy)benzoate (45).

To a solution of **21** (0.50 g, 2.06 mmol) in DMF (5 mL) Cs₂CO₃ (0.34 g, 1.03 mmol) was added and after 10 min **44** (0.50 g, 2.06 mmol). The mixture was stirred for 4 days, then poured in H₂O (30 mL) and extracted with Et₂O (3 × 20 mL). The combined organic layers were washed with a saturated solution of NaHCO₃ (30 mL), dried, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography (PE/EtOAc 9/1 v/v) to give the title compound as a colourless oil. Yield 25%. ¹H-NMR (CDCl₃) δ 1.72 (*d*, 3H, CH₃CH-, ³J_{HH} = 5.4 Hz), 2.10 (*qi*, 2H, -CH₂CH₂ONO₂), 2.30 (*s*, 3H, CH₃COO-), 3.10 (*t*, 2H, -SCH₂-, ³J_{HH} = 6.9 Hz), 4.58 (*t*, 2H, -CH₂ONO₂, ³J_{HH} = 6.0 Hz), 7.11 (*d*, 1H, C₆H₄), 7.27-7.34 (*m*, 4H, C₆H₄ + CH₃CH-), 7.58 (*t*, 1H, C₆H₄), 7.97 (*d*, 2H, C₆H₄), 8.04 (*d*, 1H, C₆H₄). ¹³C-NMR (CDCl₃) δ 19.8, 21.0, 26.1, 28.2, 71.0, 89.6, 122.5, 123.9, 126.1, 126.4, 127.0, 130.5, 132.0, 134.4, 143.3, 150.9, 162.4, 164.0, 169.6. MS (CI) *m/z* 463 (M+1)⁺.

{[2-(Acetyloxy)benzoyl]oxy}methyl 6-[(nitrooxy)methyl]pyridine-2-carboxylate (46).

A solution of **40** (0.10 g, 0.29 mmol) in (CH₃CO)₂O (0.30 mL) was slowly added to a mixture of 65% HNO₃ (0.10 mL) and (CH₃CO)₂O (0.20 mL), stirred at 0 °C. Then the reaction mixture was allowed to reach room temperature and the stirring was continued for 2 h. The mixture was poured into H₂O (10 mL) and extracted with CH₂Cl₂ (5 × 5 mL). The organic layers were dried, filtered and concentrated under reduced pressure. The crude product so obtained was purified by flash chromatography (CH₂Cl₂/EtOAc 95/5 v/v) to give the title compound as a colourless oil that became solid on standing. M.p. 73-78°C. Yield 50%. ¹H-NMR (CDCl₃) δ 2.37 (*s*, 3H, CH₃COO-), 5.67 (*s*, 2H, -CH₂ONO₂), 6.26

(*s*, 2H, -OCH₂O-), 7.13 (*d*, 1H, C₆H₄), 7.33 (*t*, 1H, C₆H₄), 7.58-7.64 (*m*, 2H, C₅H₃N), 7.93 (*t*, 1H, C₆H₄), 8.09-8.17 (*m*, 2H, C₆H₄ + C₅H₃N). ¹³C-NMR (CDCl₃) δ 21.0, 73.9, 80.5, 121.8, 124.0, 125.4, 125.6, 126.2, 132.3, 134.8, 138.4, 147.0, 151.2, 153.8, 162.8, 163.2, 169.7. MS (CI) *m/z* 391 (M+1)⁺.

{2-[3-(Nitrooxy)propoxy]benzoyl}oxy)methyl 2-(hydroxy)benzoate (47).

6M HCl (4 mL) was added to a solution of **32** (0.20 g, 0.46 mmol) in 1,4-dioxane (4 mL) and the mixture was heated at 70 °C for 6h. Then it was poured in H₂O (20 mL) and extracted with CH₂Cl₂ (3 × 30 mL). The combined organic layers were dried, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography (PE/EtOAc 90/10 v/v) to give the title compound as a colourless oil. Yield 78%. ¹H-NMR (CDCl₃) δ 2.22 (*qi*, 2H, -CH₂CH₂ONO₂), 4.13 (*t*, 2H, -OCH₂CH₂-, ³J_{HH} = 5.7 Hz), 4.72 (*t*, 2H, -CH₂ONO₂, ³J_{HH} = 6.0 Hz), 6.23 (*s*, 2H, -OCH₂O-), 6.87-7.04 (*m*, 4H, C₆H₄), 7.46-7.54 (*m*, 2H, C₆H₄), 7.89-7.93 (*m*, 2H, C₆H₄), 10.46 (*s*, 1H, OH). ¹³C-NMR (CDCl₃) δ 26.9, 64.2, 69.8, 79.5, 111.4, 113.1, 117.7, 118.3, 119.5, 120.7, 130.3, 132.6, 134.8, 136.6, 158.8, 162.0, 164.2, 169.0. MS (CI) *m/z* 392 (M+1)⁺.

Evaluation of stability in buffered solutions and in human serum.

Hydrolysis in acidic medium (pH 1.0) and in phosphate buffer (pH 7.4). A 2 mL aliquot of 0.5 mM solution of each compound in acetonitrile was diluted to 10 mL using HCl to reach pH 1.0 or phosphate buffer 50 mM to obtain pH 7.4. The resulting solution was maintained at 37 ± 0.5 °C and at appropriate time intervals a 20 µL aliquote of reaction solution was analysed by RP-HPLC. All experiments were performed in triplicate.

Hydrolysis in human serum. A solution of each compound (10 mM) in acetonitrile was added to human serum (sterile-filtered from human male AB plasma, Sigma-Aldrich) preheated at 37 °C; the final concentration of the compound was 250 µM. The resulting solution was incubated at 37 ± 0.5 °C and at appropriate time intervals 300 µL of the reaction mixture was withdrawn and added to 450 µL of acetonitrile containing 0.1% trifluoroacetic acid in order to deproteinize the serum. The sample was sonicated, vortexed and then centrifuged for 10 min at 2150 g, the clear supernatant was filtered by

0.45 μm PTFE filters (Alltech) and analysed by RP-HPLC. All experiments were performed at least in triplicate.

The reverse-phase HPLC procedure allowed separation and quantitation of the remaining compound and of the products of hydrolysis (aspirin, salicylic acid, salicylate and nitrooxy-substituted carboxylic acid). HPLC analyses were performed with a HP 1100 chromatograph system (Agilent Technologies, Palo Alto, CA, USA) equipped with a quaternary pump (model G1311A), a membrane degasser (G1379A), a diode-array detector (DAD) (model G1315B) integrated in the HP1100 system. Data analysis was done using a HP ChemStation system (Agilent Technologies). The injection volume was 20 μL (Rheodyne, Cotati, CA). The analytical column was a Nucleosil 100-5C18 Nautilus (250 \times 4.6 mm, 5 μm particle size) (Macherey-Nagel) eluting with a flow-rate of 1.2 mL/min. The samples were analysed using a gradient method employing a mobile phase consisting of acetonitrile/water with 0.1% trifluoroacetic acid 55/45 over the first 4 min, grading to 70/30 to 6 min, keeping 70/30 until 15 min and then back to 55/45 to 20 min. The column effluent was monitored at 226 nm (for compounds, aspirin and nitrooxy-substituted carboxylic acids) and at 240 nm (for salicylic acid and salicylates) referenced against a 600 nm wavelength. Quantitation was done by comparison of peak areas with standards chromatographed under the same conditions.

Inhibition of Platelet Aggregation in vitro.

Venous blood samples were obtained from healthy volunteers who had not taken any drug for at least two weeks. Volunteers, who were treated according to Helsinki protocol for biomedical experimentation, gave their informed consent to the use of blood samples for research purposes. Platelet rich plasma (PRP) was prepared by centrifugation of citrated blood at 210 g for 20 min. Aliquots (500 μL) of PRP were added into aggregometer (Chrono-log 4902D) cuvettes and aggregation was recorded as increased light transmission under continuous stirring (1000 rpm) at 37 $^{\circ}\text{C}$ for 10 min after addition of the stimulus. Collagen at submaximal concentration (0.8-1.5 $\mu\text{g}/\text{mL}$) was used as a platelet activator in PRP. Compounds under study were preincubated with PRP 10 min before addition of the

stimulus (collagen). Vehicle alone (0.5% DMSO) added to PRP did not affect platelet function in control samples. At least 5 experiments for each compound were performed.

The antiaggregatory activity of tested compounds is evaluated as % inhibition of platelet aggregation compared to control samples. For most active compounds IC_{50} values could be calculated by non-linear regression analysis, otherwise % inhibition at maximal concentration tested (300 μ M) is reported.

Vasodilator Activities.

Thoracic aortas were isolated from male Wistar rats weighing 180 - 200 g. As few animals as possible were used. The purposes and the protocols of our studies have been approved by the Ministero della Salute, Rome, Italy. The endothelium was removed, the vessels were cut helically and three strips were obtained from each aorta. The tissues were mounted under 1.0 g tension in organ baths containing 30 mL of Krebs-bicarbonate buffer with the following composition (mM): NaCl 111.2, KCl 5.0, $CaCl_2$ 2.5, $MgSO_4$ 1.2, KH_2PO_4 1.0, $NaHCO_3$ 12.0, glucose 11.1, maintained at 37 °C and gassed with 95% O_2 -5% CO_2 (pH = 7.4). The aortic strips were allowed to equilibrate for 1.5 h and then contracted with 1 μ M L-phenylephrine. When the response to the agonist reached a plateau, cumulative concentrations of the vasodilating agent were added. Results are expressed as $EC_{50} \pm SEM$ (μ M). The effects of 1 μ M ODQ on relaxation were evaluated in a separate series of experiments in which it was added 5 min before the contraction. With this protocol the inhibitor is preincubated for at least 30 min before the addition of the vasodilator compound. Responses were recorded by an isometric transducer connected to the MacLab System PowerLab. Addition of the drug vehicle, DMSO, had no appreciable effect on contraction level. At least 5 experiments for each compound were performed.

Acknowledgment. This work was supported by a MIUR grant (COFIN 2005).

Supporting information available. Elemental analyses. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Figure 1. The time-course of the metabolites of product **32** at 10 min and at 2 hours incubation time in human serum: values are mean \pm SEM (SEM \leq 5; number of determinations = 3).





Figure 2. The time-course of the metabolites of product **36** at 10 min and at 2 hours incubation time in human serum: values are mean \pm SEM (SEM \leq 5; number of determinations = 3).





Figure 3. Linear correlation between AUC values of aspirin released in human serum from the indicated compounds and the corresponding antiaggregatory IC₅₀ values.







Figure 4. Concentration response curves for vasodilator activity of the compound **36** and of its corresponding nitrooxy-substituted acid **18**, in the absence and in the presence of ODQ.



Scheme 1^a




^a Reagents and conditions: a) AgNO₃, CH₃CN, 70 °C; b) KMnO₄, Acetone; c) (Sia)₂BH, dry THF then NaOH, H₂O₂; d) H₂O/MeOH, 4M HCl, 60 °C; e) Ph₃P, NBS, CH₃CN; f) mCPBA, CH₂Cl₂, -78 °C; g) 85 %H₂O₂, CF₃COOH; h) I₂, AgNO₃, CH₃CN r.t. then AgNO₃, CH₃CN reflux.

Scheme 2^a

| R | X | Position | n | m | RCOOH number | Compound A number |
|------------------------|-----------------|-----------------|----------|----------|-------------------------|--------------------------|
| | - | - | 2 | 0 | 1 ²⁵ | 28 |
| $(\text{ONO}_2)_m$ | - | - | 2 | 1 | 2 ²⁶ | 29 |
| | - | - | 3 | 0 | 3 ²⁷ | 30 |
| | - | - | 3 | 1 | 4 ²⁸ | 31 |
| | O | Orto | 1 | 0 | 11 | 32 |
| $(\text{ONO}_2)_m$ | O | Meta | 1 | 0 | 12 | 33 |
| | O | Para | 1 | 0 | 13 | 34 |
| | O | Para | 1 | 1 | 14 ²⁹ | 35 |
| | CH ₂ | Para | 0 | 0 | 18 | 36 |
| | CH ₂ | Para | 0 | 1 | 19 ²⁹ | 37 |
| | S | Para | 1 | 0 | 21 | 38 |
| | S | Para | 1 | 1 | 25 | 39 |
| | - | - | - | - | 26 ³⁰ | 40 |

^a Reagents and conditions: a) Cs₂CO₃, DMF.

Scheme 3^a



^a Reagents and conditions: a) mCPBA, CH₂Cl₂, -78 °C; b) Oxone, H₂O/MeOH; c) CH₃CHO, ZnCl₂, CH₂Cl₂; d) **21**, Cs₂CO₃, DMF; e) (CH₃CO)₂O, 65% HNO₃, CH₂Cl₂; f) 6M HCl, 1,4-dioxane, 70 °C

Scheme 4. Possible hydrolytic routes of aspirin (acyloxy)alkyl esters to salicylic acid.






Chart 1. Examples of NO-donors-aspirin.



NCX4040 R = p-CH₂ONO₂


NCX4016 R = m-CH₂ONO₂

NCX4060 R = o-CH₂ONO₂



R' = CH₃, CONH₂, CN n = 0, m = 0

R' = Ph, PhSO₂ n = 2, m = 1



R'' = alkyl groups


Table 1. Stability of the compounds **28-39**, **41**, **42**, **45** and **46** in buffered solutions (percentage of unchanged compound after 3 hours); stability in human serum (half-life, percent of maximal amounts of aspirin released and AUC values at 10 min) and antiaggregatory activities.

| Compound | Stability in buffered solutions | | Stability in human serum | | | Platelet Aggregation | |
|-----------|----------------------------------|-----|-------------------------------|---|--------------|--------------------------------|--|
| | % unchanged at 3 h ^{a)} | | $t_{1/2}$ (min) ^{b)} | % max of aspirin released ^{c)} | AUC at 10min | IC ₅₀ (μM) (CL 95%) | % inhibition ± SEM at 300 μM ^{d)} |
| pH 1.0 | pH 7.4 | | | | | | |
| aspirin | 90 | 90 | 63 | - | - | 54 (49-60) | |
| 28 | 99 | 99 | < 1 | 10.1 | 93.6 | ^{d)} | 17 ± 3 |
| 29 | 99 | 99 | < 1 | 10.6 | 84.6 | ^{d)} | 8.6 ± 5.8 |
| 30 | 99 | 100 | < 1 | 17.6 | 153.7 | ^{d)} | 29 ± 3 |
| 31 | 99 | 99 | < 1 | 9.8 | 86.6 | ^{d)} | 36 ± 14 |
| 32 | 99 | 98 | < 1 | 5.0 | 43.6 | 163 (132-198) | |
| 33 | 99 | 98 | 1.4 | 48.3 | 387.6 | 100 (81-122) | |
| 34 | 99 | 99 | 3.4 | 39.8 | 236.7 | 138 (105-181) | |
| 35 | 99 | 99 | 5.4 | 22.4 | 105.2 | 140 (119-163) | |
| 36 | 98 | 100 | 1.9 | 65.2 | 521.6 | 41 (35-49) | |
| 37 | 99 | 99 | 3.4 | 34.2 | 220.1 | 97 (82-115) | |
| 38 | 99 | 99 | 2.4 | 61.7 | 403.3 | 45 (36-56) | |
| 39 | 98 | 98 | 4.6 | 43.0 | 192.2 | 129 (116-145) | |
| 41 | 98 | 90 | < 1 | 70.7 | 301.0 | 72 (66-78) | |
| 42 | 98 | 70 | < 1 | 59.2 | 515.8 | 38 (34-44) | |
| 45 | 98 | 99 | 4.4 | 29.4 | 144.6 | ^{d)} | 27 ± 4 |
| 46 | 84 | 60 | < 1 | 58.0 | 542.8 | 20 (15-25) | |

a) SEM ≤ 1%. b) SEM ≤ 0.2. c) SEM ≤ 2.5%. d) Due to the low activity of the compound, IC₅₀ could not be calculated: in this case the percent of inhibition is reported at 300 μM.

Table 2. Vasodilator activities of the products **1-4, 11-14, 18, 19, 21-23, 25, 28-39, 41, 42, 45, 46** and

48.



| R | X | Position | n | m | Y | Compound | Vasodilator activity | |
|-----------------|-----------------|----------|---|----------------|----------------|-------------|-----------------------------|--|
| | | | | | | | EC ₅₀ (μM) ± SEM | EC ₅₀ (μM) ± SEM + 1 μM ODQ |
| | - | - | 2 | 0 | Y ₁ | 1 | 8.3 ± 1.4 | a) |
| | - | - | 2 | 0 | Y ₂ | 28 | 1.2 ± 0.2 | b) |
| | - | - | 2 | 1 | Y ₁ | 2 | 5.8 ± 0.8 | a) |
| | - | - | 2 | 1 | Y ₂ | 29 | 0.39 ± 0.06 | b) |
| | - | - | 3 | 0 | Y ₁ | 3 | 20 ± 3 | a) |
| | - | - | 3 | 0 | Y ₂ | 30 | 1.6 ± 0.2 | b) |
| | - | - | 3 | 1 | Y ₁ | 4 | 6.8 ± 0.4 | a) |
| | - | - | 3 | 1 | Y ₂ | 31 | 0.52 ± 0.09 | b) |
| | O | Orto | 1 | 0 | Y ₁ | 11 | 20 ± 2 | a) |
| | O | Orto | 1 | 0 | Y ₂ | 32 | 4.0 ± 1.2 | b) |
| | O | Meta | 1 | 0 | Y ₁ | 12 | 3.8 ± 0.5 | a) |
| | O | Meta | 1 | 0 | Y ₂ | 33 | 0.14 ± 0.03 | b) |
| | O | Para | 1 | 0 | Y ₁ | 13 | 0.62 ± 0.07 | 66 ± 12 |
| | O | Para | 1 | 0 | Y ₂ | 34 | 0.017 ± 0.003 | b) |
| | O | Para | 1 | 1 | Y ₁ | 14 | 0.28 ± 0.04 | 67 ± 6 |
| | O | Para | 1 | 1 | Y ₂ | 35 | 0.041 ± 0.007 | b) |
| | CH ₂ | Para | 0 | 0 | Y ₁ | 18 | 0.51 ± 0.08 | a) |
| | CH ₂ | Para | 0 | 0 | Y ₂ | 36 | 0.075 ± 0.014 | b) |
| | CH ₂ | Para | 0 | 1 | Y ₁ | 19 | 0.33 ± 0.06 | a) |
| | CH ₂ | Para | 0 | 1 | Y ₂ | 37 | 0.052 ± 0.007 | b) |
| | S | Para | 1 | 0 | Y ₁ | 21 | 0.27 ± 0.05 | 53 ± 15 |
| | S | Para | 1 | 0 | Y ₂ | 38 | 0.15 ± 0.02 | b) |
| | S | Para | 1 | 0 | Y ₃ | 45 | 0.14 ± 0.03 | b) |
| | S | Para | 1 | 1 | Y ₁ | 25 | 0.27 ± 0.04 | 56 ± 16 |
| | S | Para | 1 | 1 | Y ₂ | 39 | 0.10 ± 0.03 | b) |
| | SO | Para | 1 | 0 | Y ₁ | 22 | 6.0 ± 0.7 | a) |
| | SO | Para | 1 | 0 | Y ₂ | 41 | 0.47 ± 0.07 | b) |
| | SO ₂ | Para | 1 | 0 | Y ₁ | 23 | 20 ± 2 | a) |
| SO ₂ | Para | 1 | 0 | Y ₂ | 42 | 0.36 ± 0.09 | b) | |
| | - | - | - | - | Y ₁ | 48 | 12 ± 3 | a) |
| | - | - | - | - | Y ₂ | 46 | 0.82 ± 0.10 | b) |

a) The maximal concentration tested (100 μM) cannot reach the 50 % of the effect. b) The maximal concentration tested (30 μM due to insolubility limits) cannot reach the 50 % of the effect.

References

- (1) Singh, G.; Triadafilopoulos, G. Epidemiology of NSAID induced gastrointestinal complications. *J. Rheumatol.* **1999**, *26 (Sup. 56)*, 18-24.
- (2) Morgan, G. The established and emerging uses of aspirin. *Basic Clin. Pharmacol.* **2006**, *99*, 283-286.
- (3) Patrono, C.; Rocca, B. Aspirin: promise and resistance in the new millennium. *Arterioscl. Throm. Vasc. Biol.* **2008**, *28*, S25-S32.
- (4) Yasuda, O.; Takemura, Y.; Kawamoto, H.; Rakugi, H. Aspirin: recent developments. *Cell. Mol. Life Sci.* **2008**, *65*, 354-358.
- (5) Arber, N.; Levin, B. Chemoprevention of colorectal cancer: ready for routine use? *Curr. Top. Med. Chem.* **2005**, *5*, 517-525.
- (6) Schoen, R.T.; Vender, R.J. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. *Am. J. Med.* **1989**, *86*, 449-458.
- (7) Wolfe, M.M.; Lichtenstein, D.R.; Singh, G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. *New Engl. J. Med.* **1999**, *340*, 1888-1899.
- (8) Rainsford, K.D.; Whitehouse, M.W. Gastric irritancy of aspirin and its congeners: anti-inflammatory activity without this side-effect. *J. Pharm. Pharmacol.* **1976**, *28*, 599-601.
- (9) Nielsen, N.M.; Bundgaard, H. Evaluation of glycolamide esters and various other esters of aspirin as true aspirin prodrugs. *J. Med. Chem.* **1989**, *32*, 727-734, and references therein reported.
- (10) Wallace, J.L.; Granger, D.N. The cellular and molecular basis of gastric mucosal defence. *FASEB J.* **1996**, *10*, 731-740.

- (11) Lefer, A.M.; Lefer, D.J. Therapeutic role of nitric oxide donors in the treatment of cardiovascular disease. *Drug Future* **1994**, *19*, 665-672.
- (12) Kerwin, J.F.Jr.; Lancaster, J.R.; Feldman, P.L. Nitric oxide: a new paradigm for second messengers. *J. Med. Chem.* **1995**, *38*, 4343-4362.
- (13) Miller, M.R.; Megson, I.L. Recent developments in nitric oxide donor drugs. *Br. J. Pharmacol.* **2007**, *151*, 305-321.
- (14) Wallace, J.L. Building a better aspirin: gaseous solutions to a century-old problem. *Br. J. Pharmacol.* **2007**, *152*, 421-428, and references therein.
- (15) Wang, P.G.; Xian, M.; Tang, X.; Wu, X.; Wen, Z.; Cai, T.; Janczuk, A.J. Nitric oxide donors: chemical activities and biological applications. *Chem. Rev.* **2002**, *102*, 1091-1134.
- (16) Gilmer, J.F.; Moriarty, L.M.; Clancy, J.M. Evaluation of nitrate-substituted pseudocholine esters of aspirin as potential nitro-aspirin. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 3217-3220.
- (17) Cena, C.; Lolli, M.L.; Lazzarato, L.; Guaita, E.; Morini, G.; Coruzzi, G.; McElroy, S.P.; Megson, I.L.; Fruttero, R.; Gasco, A. Antiinflammatory, gastrosparring, and antiplatelet properties of new NO-donor esters of aspirin. *J. Med. Chem.* **2003**, *46*, 747-754.
- (18) Velázquez, C.; Rao, P.N.P.; Knaus, E.E. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: design, synthesis, biological evaluation, and nitric oxide release studies. *J. Med. Chem.* **2005**, *48*, 4061-4067.
- (19) Velázquez, C.A.; Rao, P.N.P.; Citro, M.L.; Keefer, L.K.; Knaus, E.E. *O*²-Acetoxymethyl-protected diazeniumdialate-based NSAIDs (NONO-NSAIDs): synthesis, nitric oxide release, and biological evaluation studies. *Bioorg. Med. Chem.* **2007**, *15*, 4767-4774.
- (20) Velázquez, C.A.; Chen, Q-H.; Citro, M.L.; Keefer, L.K.; Knaus, E.E. Second-generation aspirin

- and indomethacin prodrugs possessing an *O*-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1,2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studies. *J. Med. Chem.* **2008**, *51*, 1954-1961.
- (21) Carini, M.; Aldini, G.; Orioli, M.; Maffei Facino, R. In vitro metabolism of a nitroderivative of acetylsalicylic acid (NCX4016) by rat liver: LC and LC-MS studies. *J. Pharmaceut. Biomed.* **2002**, *29*, 1061-1071.
- (22) Gao, J.; Kashfi, K.; Rigas, B. In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism. *J. Pharmacol. Exp. Ther.* **2005**, *312*, 989-997.
- (23) Rao, C.V.; Joseph, S.; Gao, L.; Patrolla, J.M.R.; Choi, C.I.; Kopelovich, L.; Steele, V.E.; Rigas, B. Pharmacokinetic and pharmacodynamic study of NO-donating aspirin in F344 rats. *Int. J. Oncol.* **2008**, *33*, 799-805.
- (24) Agersborg, H.P.K.; Batchelor, A., Cambridge, G.W.; Rule, A.W. The pharmacology of penamecillin. *Br. J. Pharmacol.* **1966**, *26*, 649-655.
- (25) Garvey, D.S.; Letts, G.; Earl, R.A.; Ezawa, M.; Fang, X.; Gaston, R.D.; Khanapure, S.P.; Lin, C-E.; Ranatunge, R.R.; Stevenson, C.A.; Wey, J-J. Nitric oxide enhancing diuretic compounds, compositions and methods of use. Patent Application Publication US2006/0189603, August 24, 2006.
- (26) Lazzarato, L.; Rolando, B.; Lolli, M.L.; Tron, G.C.; Fruttero, R.; Gasco, A.; Deleide, G.; Guenther, H.L. Synthesis of NO-donor bisphosphonates and their in vitro action on bone resorption. *J. Med. Chem.* **2005**, *48*, 1322-1329.
- (27) Song, H.; Li, J.; Wang, Y.; Zhang, S.; Liu, Y.; Ren, Z. Synthesis and anti-inflammatory/analgesia activities of pyrrolizinones. *Zhongguo Yaowu Huaxue Zazhi* **2005**, *15*,

266-270.

- (28) Lazzarato, L.; Donnola, M.; Rolando, B.; Marini, E.; Cena, C.; Coruzzi, G.; Guaita, E.; Morini, G.; Fruttero, R.; Gasco, A.; Biondi, S.; Ongini, E. Searching for new NO-donor aspirin-like molecules: a new class of nitrooxy-acyl derivatives of salicylic acid. *J. Med. Chem.* **2008**, *51*, 1894-1903.
- (29) Chegaev, K.; Lazzarato, L.; Rolando, B.; Marini, E.; Tosco, P.; Cena, C.; Fruttero, R.; Bertolini, F.; Reist, M.; Carrupt, P-A.; Lucini, V.; Frascini, F.; Gasco, A. NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterization. *J. Pineal Res.* **2007**, *42*, 371-385.
- (30) Breschi, M.C.; Calderone, V.; Digiaco, M.; Macchia, M.; Martelli, A.; Martinotti, E.; Minutolo, F.; Rapposelli, S.; Rossello, A.; Testai, L.; Balsamo, A. New NO-releasing pharmacodynamic hybrids of Losartan and its active metabolite: design, synthesis, and biopharmacological properties. *J. Med. Chem.* **2006**, *49*, 2628-2639.
- (31) Buchwald, P. Structure-metabolism relationships: steric effects and the enzymatic hydrolysis of carboxylic esters. *Mini Rev. Med. Chem.* **2001**, *1*, 101-111.
- (32) Weber, A.A.; Neuhaus, T.; Seul, C.; Dusing, R.; Schror, K.; Sachinidis, A.; Vetter, H. Biotransformation of glyceryl trinitrate by blood platelets as compared to vascular smooth muscle cells. *Eur. J. Pharmacol.* **1996**, *309*, 209-213.
- (33) Poradosu, E.; Gazit, A.; Reuveni, H.; Levitzki, A. α -Cyanocinnamide derivatives: a new family of non-peptide, non-sulphydryl inhibitors of Ras farnesilation. *Bioorg. Med. Chem.* **1999**, *7*, 1727-1736.
- (34) Cai, Z.; Feng, J.; Guo, Y.; Li, P.; Shen, Z.; Chu, F.; Guo, Z. Synthesis and evaluation of

azaindole- α -alkyloxyphenylpropionic acid analogues as PPAR α/γ agonists. *Bioorg. Med. Chem.*

2006, *14*, 866-874.

- (35) Bancroft, S.F.; Thompson, M.J.; Frimpong, N.; Mullins, R.J.; Pugh, C. Synthesis and thermotropic behavior of polynorbornenes with laterally attached 2,5-bis[(4'-n-alkylthiobenzoyl)oxy]benzyl mesogens. *Polymer Preprints* **2007**, *48*, 1001-1002.
- (36) Wrobel, J.; Green, D.; Jetter, J.; Kao, W.; Rogers, J.; Claudia Perez, M.; Hardenburg, J.; Deecher, D.C.; Lopez, F.J.; Arey, B.J.; Shen, E.S. Synthesis of (bis)sulfonic acid, (bis)benzamides as follicle-stimulating hormone (FSH) antagonists. *Bioorg. Med. Chem.* **2002**, *10*, 639-656.
- (37) Fechtig, B. 7-Beta-acylamido-3-cephem-4-carboxylic-acid esters, process for their preparation, pharmaceutical compositions and their application. European patent EP0136266, September 17, 1984.
- (38) Pellegata, R.; Italia, A.; Villa, M.; Palmisano, G.; Lesma, G. A facile preparation of primary carboxamides. *Synthesis* **1985**, 517-519.
- (39) Green, T. W., Wuts, P. G. M. Protection for the carbonyl group. In *Protective Groups in Organic Synthesis*, third ed.; John Wiley & Sons, New York, 1999; pp 293-368.

**(NITROOXYACYLOXY)METHYL
ESTERS OF ASPIRIN AS NOVEL
NITRIC OXIDE RELEASING ASPIRINS**

Loretta Lazzarato, Monica Donnola, Barbara Rolando, Konstantin Chegaev, Elisabetta Marini, Clara Cena, Antonella Di Stilo, Roberta Fruttero, Stefano Biondi, Ennio Ongini, Alberto Gasco.*

